First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Replimune Group, Inc. (REPL): the developments shaping its investment case

    Follow the evidence affecting Replimune Group, Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Replimune Group, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-08-14 · 2 reports
    Replimune Group, Inc. Follow-On — $150M
    Channel: Enhanced financial stability and ability to execute strategic growth initiatives.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-10multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-08-10share_countBullishPrimary equity issuance increases diluted share count.
    2026-06-29net_debtBullishCash balance decreased from $483.8M to $268.9M year-over-year due to operating burn.
    2026-06-29revenueBullishFDA goal date of August 2, 2026 for RP1 BLA resubmission could lead to first commercial revenue.
    2026-06-29net_debtBullishCash and short-term investments decreased from $483.8M to $268.9M year-over-year due to high operating burn.

    Event impact log

    2 events mapped to REPL since 2026-08-14. Evidence through 2026-08-14.

    DateEventChannelDirectionHorizonImpact
    2026-08-14Replimune Group, Inc. Follow-On — $150MEnhanced financial stability and ability to execute strategic growth initiatives.Bullish3-12m0.60
    2026-08-14Replimune Group, Inc. Follow-On — $150MDirect equity dilution and increased cash reserves for operational funding.mixed1-3m0.70

    Continue this research

    Build your Replimune Group, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the REPL entity page →

    Research Replimune Group, Inc. · $399/mo